Notice of Allowability	Application No.	Applicant(s)	
	10/084,235 Examiner	REED ET AL.	
	Barbara P. Badio, Ph.D.	1617	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to			
2. The allowed claim(s) is/are <u>7.8 and 10-16</u> .			
<ul> <li>3. X Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) X All b) Some* c) None of the: <ol> <li>Certified copies of the priority documents have been received.</li> <li>Certified copies of the priority documents have been received in Application No</li></ol></li></ul>			
<ol> <li>DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT</li> </ol>			
Attachment(s) 1.  Notice of References Cited (PTO-892)	5 🗖 Notice of Information	Patent Application (PTO-152)	
<ol> <li>Notice of Preferences Cited (PTO-692)</li> <li>2. Notice of Draftperson's Patent Drawing Review (PTO-948)</li> </ol>	6. X Interview Summary		
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0	Paper No./Mail Da	Paper No./Mail Date 7. I Examiner's Amendment/Comment	
Paper No./Mail Date 4.  Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🗌 Examiner's Stateme 9. 🗌 Other	ent of Reasons for Allowance	
· ·		· · · · · · · · · · · · · · · · · · ·	

.

.

## **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Angela Collison on November 15, 2005.

The application has been amended as follows:

Claims 6, 9 and 17-20 have been cancelled.

Claim 12 has been rewritten as follows: --

•

.

12. The pharmaceutical composition according to any one of claims 7, 8, 10 or 11 wherein  $R_1$  and  $R_2$  are independently selected from H, or a  $C_1$ - $C_5$  alkyl; but wherein at least one of  $R_1$  and  $R_2$  is H.

## Drawings

2. The Examiner accepts drawings filed February 25, 2002.

## **Telephone Inquiry**

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Barbara P. Badio, Ph.D. whose telephone number is 571-272-0609. The examiner can normally be reached on M-F from 6:30am-4:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Barbara P. Badio, Ph.D.

Barbara P. Badio, Ph.D. Primary Examiner Art Unit 1617

BB November 15, 2005